





LWestaby EditorialAprotinin: Twenty-five years of claim and counterclaim
Stephen Westaby, PhD, FECTS, FACC
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he coagulopathy after blood–foreign surface interaction in the cardiopulmo-
nary bypass circuit is part of the ‘‘postperfusion syndrome,’’ which historically
has accounted for as many deaths as has cardiac insufficiency. Cardiopulmo-
nary bypass induces platelet dysfunction, thrombin production, and plasmin release.1
These changes provide the basis for postoperative hemorrhage, cardiac tamponade,
and the need for surgical re-entry or excessive blood transfusion. Antiplatelet therapy
in patients with coronary artery disease further compounded these effects. In turn,
transfusion of packed red blood cells and coagulation components is recognized to
increase the risk of morbidity and mortality after cardiac surgery.2,3
An Important Discovery
In the early 1980s, the Kirklin group in Alabama began to pursue the pathophysio-
logic mechanisms underlying the postperfusion syndrome. In short, blood–foreign
surface interaction and protamine administration were both found to activate comple-
ment. Complement anaphylatoxins caused neutrophil activation, intrapulmonary
white cell sequestration, and release of protease enzymes and free radicals. Twenty-
five years ago at the Hammersmith Hospital, my colleagues and I sought to attenuate
the inflammatory response by using the only commercially available protease inhib-
itor, aprotinin, which had been used unsuccessfully to treat pancreatitis. At this stage,
no interaction was known or anticipated between aprotinin and the coagulation
system. The hemostatic mechanism was discovered when the surgical field was noted
to be abnormally dry after cardiopulmonary bypass. As the therapeutic potential
became apparent, guidelines for aprotinin use were developed by trial and error. Using
the standard celite–activated clotting time (ACT) of greater than 450 seconds for
heparin monitoring, blood often set solid in the pericardium with a shiny glazed
appearance. Intraoperative events such as spontaneous vein graft thrombosis or clot-
ting within the oxygenator were not uncommon until it was recognized that aprotinin
alone prolonged the celite ACT and the in vitro activated partial thromboplastin time.4
This has important implications for heparin dosage. An inhibitory effect on the endo-
thelial cell anticoagulant function may also have consequences during hypothermic
low flow and circulatory arrest states.5 Thus many early patients were inadequately
anticoagulated at stages of their operation.
With generous financial support from the Bayer Corporation (Leverkusen, Ger-
many), a number of clinical and scientific studies showed the hemostatic mechanism
to result from protection of platelet adhesive receptors at the onset of cardiopulmonary
bypass.6 Without aprotinin, the contact system of plasma is massively activated on
first passage through the oxygenator. Activation of the intrinsic coagulation pathway
causes thrombin formation, which impairs platelet adhesive function. Aprotinin also
blocks the contact activation of the kallikrein system and, in synergy with heparin,
prevents thrombin formation through inhibition of the intrinsic clotting cascade.7
Although this is not the whole story, it is likely that neither thrombin nor platelets
become involved in the blood–foreign surface contact activation process in aproti-
nin-treated patients. The fact that the hemostatic process is affected from the very
beginning of cardiopulmonary bypass is substantiated by the fact that low-dose
aprotinin (23 106 KIU) added to the pump prime leads to the same preservation effect
on platelet receptors and blood loss as continuous high-dose infusion (6 3 106 KIU)
throughout the procedure. This observation had clinical implications inasmuch as
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ACT 5 activated clotting time
BART 5 Blood Conservation using Antifibrinolytics:
A Randomized Trial in High-Risk Cardiac
Surgery Patients
CABG 5 coronary artery bypass grafting
FDA 5 Food and Drug Administration
HCA 5 hypothermic circulatory arrest
a single pump prime dose of aprotinin was much less expen-
sive than the high-dose ‘‘Hammersmith regimen.’’
Aprotinin became commercially available and enjoyed
widespread use in Europe before these mechanisms were
fully elucidated. First licensed for use in patients at high
risk of postoperative bleeding (reoperations, endocarditis,
multiple valve replacements), the indications were soon
extended to the commercially important realm of coronary
bypass surgery (CABG) in patients taking aspirin. Extensive
aortic surgery provided an obvious role for aprotinin, but
even after the target celite ACT was raised to greater than
700 seconds the anticoagulation of completely static blood
during hypothermic circulatory arrest would prove problem-
atic. Cooling alone prolongs the ACT, so higher doses of
heparin are needed when profound hypothermia is used
(ACT . 1000 seconds).8 During hypothermic circulatory
arrest (HCA), the endothelial cell normally produces substan-
tial amounts of tissue plasminogin activator, which produces
plasmin and activates fibrinolysis to prevent vascular occlu-
sion by fibrin. Thrombin formation during stagnation also
stimulates the protein C system of the endothelial lining.
This inhibits the actived clotting factors Va and VIIIa to
minimize coagulation. However, both plasmin and protein
C are inhibited by aprotinin. Fatal intravascular coagulation
and renal failure were encountered in early series, sparking
vigorous debate over safety and adequacy of anticoagulation
after HCA.9,10
European observational and randomized studies all
confirmed the hemostatic effect, the reduction in blood trans-
fusion requirement, and less frequent return to the operating
theater to control bleeding.11 Many European centers gave
aprotinin to every patient undergoing cardiac surgery. Differ-
ent dosage regimens were tried and most found to be effective
in reducing blood loss. Aprotinin was even used as a topical
agent in the pericardium and for postoperative infusion
during established bleeding. Few if any of the randomized
studies were powered to show differences in mortality.
Food and Drug Administration (FDA) Approval and
Beyond
Aprotinin had no license for any indication in the United
States and further studies were required with varied dose
regimens before FDA approval. Because these trials were488 The Journal of Thoracic and Cardiovascular Surgery c Maprimarily designed to show effectiveness, they were also
individually too small to establish safety. As expected, the
hemostatic effect was confirmed with a reduction in transfu-
sion requirement for so-called higher-risk patients, but there
was no significant benefit for CABG in patients without anti-
platelet therapy.12 Two trials in patients requiring reoperative
CABG reported excess mortality in the half-dose arm and in-
creased myocardial infarction rate by laboratory criteria.13,14
Cosgrove and colleagues13 raised concern over early graft
thrombosis and mortality based on autopsy findings but
with a trend that failed to meet statistical significance. Levy
and associates14 noted increased mortality and myocardial
infarction with a half-dose regimen, but the study was under-
powered for mortality (P5 .354). Lemmer and colleagues12
showed a significantly increased rate of myocardial infarction
by laboratory criteria (without elevated mortality) when only
the pump prime dose was used. In contrast, the full-dose
regimen advocated by Bayer did not elevate risk of mortality
or ischemic events, and many interpreted the results as dem-
onstrating aprotinin to be safe and effective for all patients.
Because of the persisting uncertainty surrounding adverse
events, Smith and Muhlbaier15 pooled all the raw data from
the four published US trials together with two other unpub-
lished studies obtained from the Bayer Corporation. This
allowed more powerful analysis of myocardial infarction,
stroke, renal failure, and mortality. The analysis showed
CABG mortality for half-dose aprotinin to be 5.4% compared
with 3.8% for placebo (a 42% increase), yet the number of
randomized patients (2283) was still too small to detect
statistically significant differences. Power analysis shows
that 3160 patients would be required for each group to detect
a 40% increase in mortality (from 3.8% to 5.3%). Again,
there was no difference in mortality in the larger cohort ran-
domized to high-dose aprotinin or placebo (2.7% vs 2.8%).
No difference was noted in renal dysfunction, but there was
an intriguing reduction in stroke rate for patients receiving
a full-dose regimen (1.0% vs 2.4% placebo; P 5 .27).
Royston,16 a coworker for the original Hammersmith
study, provided an elegant pathophysiologic hypothesis to
explain how low-dose therapy might cause a greater throm-
botic risk than high dosage (6 3 106 KIU). Aprotinin at
high dose inhibits both coagulation (resulting in reduced
thrombin formation) and fibrinolysis (causing less D-dimer
formation). At lower doses, the anticoagulant function medi-
ated through kallikrein inhibition is less prominent. The
plasma concentration recognized to inhibit kallikrein is 200
KIU/mL or greater whereas the plasma inhibition level is
only 50 KIU/mL. Accordingly the ‘‘Hammersmith’’ dose
aprotinin regimen combines both anticoagulant and antifibri-
nolytic effects as well as preservation of platelet function. In
contrast, low plasma concentrations maintain fibrinolysis
inhibition but lose inhibition of the intrinsic clotting cascade.








LSo that the safety of aprotinin in patients undergoing
CABG could be established, there was a need for invasive
studies of coronary graft patency. Again, these produced
conflicting information depending on the dosage regimen
and mode of investigation. Most investigators using early
graft angiography or ultrafast computed tomography sug-
gested no difference between placebo and treatment
groups.17 In contrast, a nonrandomized retrospective study
by van der Meer and colleagues18 using graft angiography
1 year after CABG showed distal anastomosis occlusion
rates of 20.5% for treated patients versus 12.7% without
aprotinin (P 5 .09). The proportion of patients with
occluded versus patent grafts was 44.1% versus 26.3%,
respectively (P 5.3). Perioperative myocardial infarction
occurred in 14.3% versus 7.0% (P 5 .12). Bayer then com-
missioned a multicenter trial using graft angiography to be
performed within a few days of surgery.19 Patients were
recruited from 10 centers in the United States, 2 in Israel,
and 1 in Denmark (designated ‘‘European centers’’). During
1994 and 1995, 870 patients were randomized to either
high-dose aprotinin or placebo. The outcome was eventu-
ally reported 2 years later at the 78th Annual Meeting of
The American Association for Thoracic Surgery (1998).
Only 703 (80%) patients had satisfactory graft angiograms,
which showed thrombotic occlusion in 15.4% of aprotinin-
treated patients versus 10.9% in the placebo group (P 5
.03). However, 1 non-US center showed an unexpectedly
high graft occlusion rate; when analysis of graft closures
was repeated for US centers only, there was no significant
difference between aprotinin and placebo.
Why were the differences in vein graft occlusion rates be-
tween the US and non-US centers so dramatic (aprotinin;
non-US 23%, US 9.4%: placebo; non-US 12.4%, US
9.5%)? Scrutiny of the data provides several explanations.
The study protocol was changed at the Israeli site after blood
for vein preparation was initially obtained from the central
venous line into which aprotinin had been administered,
and this produced a graft occlusion rate of 73% in the apro-
tinin group and an important indication of the risk of this
agent in patients with coronary disease. After procedures at
this center were revised, graft occlusion rates with aprotinin
decreased to 14% versus 3% for placebo for the remaining
two thirds of the study. There were other important differ-
ences. First, the patients were selected, not consecutive,
and the coronary surgery intervention rates in the United
States (.1000 3 106) greatly exceeded those of European
centers (,5003106). Despite this, the US centers on average
randomized only 47 patients over 2 years, of whom 90%
were male. One center randomized only 2 patients. Patients
in US centers were well documented to have larger and better
quality distal vessels. US sites also had a higher proportion of
patients receiving aspirin within 2 days of the operation,
which would favor graft patency. Consequently, the US pa-
tient cohort was less likely to have graft occlusion with orThe Journal of Thorwithout aprotinin. In contrast, European centers randomized
on average 133 patients per center, more women, more
patients with vessels less than 1.5 mm in diameter, and
more with distal disease. These variables were subsequently
identified as predisposing to graft occlusion in aprotinin-
treated patients.
Given the status of interventional cardiology in 2008, the
patients randomized in the non-US centers now clearly repre-
sent the global CABG population and could be interpreted as
‘‘at risk’’ from aprotinin during CABG. Occluded grafts are
a high price to pay for an average blood saving of 250 mL,
particularly inasmuch as pump prime volume, as well as
blood loss, determines the postoperative hematocrit in most
straightforward operations.12 There are other methods to
conserve blood, and the contrary view that hemodilution,
temporary fibrinolysis, and platelet dysfunction promote
vein graft patency is more appealing.
Claims and counterclaims over safety issues have contin-
ued over the 15 years since FDA approval in 1993. Very few
trials have been powered to detect increased mortality or
myocardial infarction rates, and because of the cost of
aprotinin, most studies have been sponsored and policed by
the manufacturers. This key issue was identified as a source
of bias by Mangano, Tudor, and Dietzel20 on publication of
their manuscript, ‘‘The Risk Associated With Aprotinin in
Cardiac Surgery.’’ The hypothesis underpinning the Man-
gano study challenged the logic of aprotinin use in patients
with acute coronary syndrome undergoing CABG who
should otherwise be subject to the contrary strategies of
platelet inhibition and fibrinolysis. This observational study
of patients undergoing CABG by the Multicentre Study of
Perioperative Ischaemia Research Group assessed the 3 anti-
fibrinolytic agents—aprotinin (1295 patients), aminocaproic
acid (883 patients), and tranexamic acid (822 patients)—as
compared with no agent (1374 patients). A propensity-
adjusted multivariate logistic regression analysis showed
aprotinin to be associated with a doubling of the risk of renal
failure requiring dialysis, a 55% increase in the risk of myo-
cardial infarction or heart failure (P 5 .001), and a 181%
increase in stroke or encephalopathy (P 5.001). The other
agents were blameless in this respect. The authors stated
the obvious by suggesting that the combination of kallikrein,
plasmin, and protein C inhibition, together with preservation
of platelet function and impairment of vasculoendothelial
function, provided a convincing substrate for the observed
thrombotic effects.
True to form, Mangano’s paper was vigorously attacked.
Royston, van Haaften, and de Vooght21 provided a scholarly
rebuttal of virtually all studies that reported adverse events
and ended emotionally with the statement ‘‘If the NEJM arti-
cle is incorrect and patients suffer increased transfusions
leading to renal failure and death because aprotinin therapy
was withheld due to fear of litigation what debt is owed to





LFurnary and colleagues22 used a nonrandomized retro-
spective observational study to contest the recurring
allegation that aprotinin predisposes to renal failure. They
suggested that aprotinin had been used in selected higher-
risk patients and that it was an increase of transfused packed
red blood cells that independently caused postoperative acute
renal failure, not aprotinin itself. Sedrakyan, Atkins, and
Treasure23 chose the Lancet to dispute Mangano’s findings.
They implied that the clinical decision to use aprotinin in
high-risk patients (the way the agent was meant to be used)
caused large differences between patient groups and that
differential exclusion of patients added bias. In fact, the
majority of Mangano’s excluded patients had received low-
dose therapy, previously identified to elevate risk, and had
7.2% mortality compared with 2.6% mortality among
included patients. Sedrakyan, Treasure, and Elefteriades24
argued that their own meta-analysis of 35 randomized but
grossly underpowered trials of CABG patients (little more
than 100 patients per trial) indicated that there was no
increased risk of myocardial infarction, renal failure, or
stroke. These authors suggested the need for a new appropri-
ately powered prospective randomized trial to compare
aprotinin with the other antifibrinolytics and signed off
with the now resounding words, ‘‘We await the findings of
the BART trial in Canada.’’
Fallout From the BART Trial
BART stands for ‘‘Blood Conservation using Antifibrino-
lytics: A Randomized Trial in High-Risk Cardiac Surgery
Patients.’’ The study was designed to test the hypothesis
that aprotinin was superior to epsilon-aminocaproic acid or
tranexamic acid in decreasing the occurrence of major
bleeding in cardiac surgery. Described as an investigator-
sponsored independent randomized controlled trial, the study
intended to enroll around 3000 adult patients in Canada who
fulfilled the criteria for elevated risk of postoperative
bleeding. However, on October 19, 2007, the Data Safety
Monitoring Board informed the FDA that at an interim anal-
ysis the 30-day mortality in the aprotinin group had already
virtually reached conventional statistical significance when
compared with the other agents. A trend toward higher
mortality had been apparent for the aprotinin group through-
out the study (relative risk of 1.5 compared with the other
agents). Paradoxically, more deaths from hemorrhage were
recorded in aprotinin-treated patients. The Data Safety Mon-
itoring Board considered that further recruitment to the study
was unlikely to change these findings, and the FDA took the
view that BART reinforced the findings of Mangano and
others who had reported increased risk of mortality with
aprotinin use. Although the FDA did not place an outright
ban on aprotinin, it issued a warning and asked for reports
of serious or unexpected adverse reactions. After this review,
Bayer and Nordic Pharma (Baarn, The Netherlands)
voluntarily suspended global marketing of the drug. The490 The Journal of Thoracic and Cardiovascular Surgery c MarCommission for Human Medicines suspended relevant
United Kingdom licenses because specific patient groups at
increased risk of mortality or those who may gain most
benefit from aprotinin could not be identified on current
information. There will now be a full risk–benefit review
by authorities in Europe and the United States.
Clinical trials involving ‘‘miscellaneous high-risk pa-
tients’’ are seldom straightforward, but this is the real world
of antifibrinolytic therapy in cardiac surgery. It is inevitable
that the BART study will be subject to the same battery of
criticism. So far, the causes of death have not been presented
in detail, but excess bleeding in aprotinin-treated patients was
a feature of some HCA case studies and followed inadequate
heparinization and disseminated intravascular coagulation.9
Greater transfusion requirement was noted for aprotinin-
treated patients in a retrospective study of aprotinin, blood
transfusion, and renal impairment by Furnary and associ-
ates.22 Whether other deaths were related to thrombotic or
bleeding events remains to be seen, but Royston’s realiza-
tion21 of the potential for litigation after any adverse event
in an aprotinin-treated patient must now be taken seriously.
Recently, in this Journal Augoustides,25 an anesthesiologist,
described fatal widespread thrombosis in 5 patients after
HCA operations in which aprotinin or epsilon-aminocaproic
acid had been used. He was convinced that standard of care
anticoagulation had been maintained throughout, but factor
V Leiden deficiency was identified in 2 of the 5 patients.
This genetically based hypercoaguable condition is found
in around 8% of cardiac surgical patients and aprotinin may
contribute to thrombosis risk by inhibition of protein C.
Most cardiac centers do not screen for factor V Leiden defi-
ciency, thus adding an unpredictable factor to antifibrinolytic
therapy in a significant proportion of patients.
My Perspective
No drug can be regarded as completely safe, and patient
variability plays an important role in susceptibility to adverse
events. Aprotinin is used in the full age spectrum from
neonatal to geriatric cardiac surgery. Since clinical trials
powered to detect adverse events emerged only after 20 years
of marketing, it is probably fair to conclude that commercial-
ization forged ahead of science. A risk–benefit analysis must
now cover all age groups and clinical conditions.
I have used aprotinin selectively since initiating the Ham-
mersmith trial in 1982. In more than 10,000 operations with
cardiopulmonary bypass, aprotinin was used in approxi-
mately 3500 patients. These all fell into so-called high-risk
groups, including early (not late) reoperation, surgery for
complex congenital heart defects, multiple (but rarely single)
valve replacements, mechanical circulatory support, endo-
carditis, and in thoracic aortic aneurysm surgery. The latter
includes patients with acute type A dissection after initially
reporting a series of adverse events, which were successfully







LI have avoided aprotinin in all patients undergoing CABG
unless subject to recent thrombolysis or clopidogrel therapy
within 48 hours of surgery. We have always looked for
drug-related adverse events and performed autopsies after
postoperative death. Since 1990 only one death with multiple
thrombotic events and clotting in the oxygenator occurred
that could have been considered aprotinin related, and in ret-
rospect that patient probably had factor V Leiden deficiency.
There have been 4 easily controlled anaphylactic events in
response to a test dose of aprotinin. At the same time, we
have achieved less than 1% mortality for elective aortic
root operations, 2% mortality for complete atrioventricular
valve defects in infancy, and 6% mortality for acute type A
dissection. These are patient groups in which aprotinin has
been used routinely for many years. With very experienced
anesthesiologists and use of the Hammersmith dosage regi-
men, we consider the risk–benefit equation to strongly favor
aprotinin use in the type of patient described. We regard
aprotinin as very safe when used selectively with close
attention to anticoagulation management and feel profoundly
disadvantaged to be left without a supply.
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